The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival.

doi:10.1097/SLA.0000000000006794

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival.

Annals of surgery - 1 Oct 2025

Campbell Brady A, Solinas Dario, Blackford Amanda L, Dal Molin Marco, Purchla Julia, McPhaul Thomas, Chidambaram Swathikan, Cameron John L, Lin Ming-Tseh, Hruban Ralph H, Shubert Christopher R, Lafaro Kelly J, Burkhart Richard A, Burns William R, He Jin

Abstract excerpt

OBJECTIVE: To evaluate whether mutations in pancreatic ductal adenocarcinoma (PDAC) driver genes ( KRAS , TP53 , SMAD4 , and CDKN2A ) are associated with pathological characteristics and prognosis. BACKGROUND: The prognostic significance of specific mutations in PDAC driver genes is incompletely understood. METHODS: We analyzed patients who underwent pancreatectomy between 2018 and 2022 for localized PDAC and...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Pancreatic Ductal
Pancreatic Neoplasms
Female
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Middle Aged

Aged

Pancreatectomy

Proto-Oncogene Proteins p21(ras)

Tumor Suppressor Protein p53

Smad4 Protein

Prognosis

Survival Rate

Retrospective Studies

Cyclin-Dependent Kinase Inhibitor p16

Source

Open in PubMed

Identifiers

PMID: 40528743
DOI: 10.1097/SLA.0000000000006794

Genes

KRAS
TP53
CDKN2A
SMAD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival.PMID 40528743Read ↗

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.Semantic proximity Read ↗

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelSemantic proximity Read ↗

Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.Semantic proximity Read ↗

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.Semantic proximity Read ↗

Pancreatic Cancer: Genetics, Screening, Prevention, and Treatment.Semantic proximity Read ↗

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.